PDS Biotechnology Corp (PDSB)
4.02
+0.24
(+6.49%)
USD |
NASDAQ |
May 08, 16:00
4.02
0.00 (0.00%)
After-Hours: 18:08
PDS Biotechnology Enterprise Value: 105.58M for May 7, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 07, 2024 | 105.58M |
| May 06, 2024 | 103.93M |
| May 03, 2024 | 107.23M |
| May 02, 2024 | 103.93M |
| May 01, 2024 | 99.52M |
| April 30, 2024 | 89.99M |
| April 29, 2024 | 91.46M |
| April 26, 2024 | 87.05M |
| April 25, 2024 | 86.69M |
| April 24, 2024 | 86.32M |
| April 23, 2024 | 84.49M |
| April 22, 2024 | 76.78M |
| April 19, 2024 | 64.13M |
| April 18, 2024 | 73.48M |
| April 17, 2024 | 66.88M |
| April 16, 2024 | 69.81M |
| April 15, 2024 | 70.55M |
| April 12, 2024 | 84.12M |
| April 11, 2024 | 90.72M |
| April 10, 2024 | 82.65M |
| April 09, 2024 | 87.05M |
| April 08, 2024 | 88.52M |
| April 05, 2024 | 85.59M |
| April 04, 2024 | 87.79M |
| April 03, 2024 | 102.09M |
| Date | Value |
|---|---|
| April 02, 2024 | 103.56M |
| April 01, 2024 | 114.56M |
| March 28, 2024 | 112.36M |
| March 27, 2024 | 108.33M |
| March 26, 2024 | 131.44M |
| March 25, 2024 | 140.61M |
| March 22, 2024 | 136.57M |
| March 21, 2024 | 146.11M |
| March 20, 2024 | 126.30M |
| March 19, 2024 | 122.33M |
| March 18, 2024 | 124.48M |
| March 15, 2024 | 129.28M |
| March 14, 2024 | 125.47M |
| March 13, 2024 | 124.31M |
| March 12, 2024 | 120.17M |
| March 11, 2024 | 131.26M |
| March 08, 2024 | 147.81M |
| March 07, 2024 | 159.72M |
| March 06, 2024 | 167.00M |
| March 05, 2024 | 159.06M |
| March 04, 2024 | 171.31M |
| March 01, 2024 | 185.21M |
| February 29, 2024 | 185.21M |
| February 28, 2024 | 161.38M |
| February 27, 2024 | 168.99M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-11.07M
Minimum
Apr 02 2020
410.73M
Maximum
Sep 23 2021
99.45M
Average
92.36M
Median
Mar 03 2022
Enterprise Value Benchmarks
| Syros Pharmaceuticals Inc | 37.14M |
| PAVmed Inc | 78.87M |
| Altimmune Inc | 318.30M |
| Regeneron Pharmaceuticals Inc | 98.34B |
| iBio Inc | 16.84M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -10.90M |
| Total Expenses (Quarterly) | 10.41M |
| EPS Diluted (Quarterly) | -0.35 |
| Earnings Yield | -34.58% |